Nurix Therapeutics IncNASDAQ:NRIX
- LAST PRICE12.4300
- TODAY'S CHANGE (%)0.0700 (0.5663%)
- Bid / Lots12.4100/ 1
- Ask / Lots12.4500/ 2
- Open / Previous Close12.4900 / 12.3600
- Day Range
- 52 Week Range
- Volume70,265
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NRIX |
|---|---|---|
| 09:32 ET | 3244 | 12.325 |
| 09:34 ET | 2900 | 12.18 |
| 09:36 ET | 200 | 12.2 |
| 09:38 ET | 760 | 12.335 |
| 09:39 ET | 576 | 12.38 |
| 09:41 ET | 200 | 12.45 |
| 09:43 ET | 900 | 12.52 |
| 09:45 ET | 3704 | 12.52 |
| 09:48 ET | 800 | 12.545 |
| 09:50 ET | 1953 | 12.54 |
| 09:52 ET | 1173 | 12.57 |
| 09:54 ET | 100 | 12.58 |
| 09:56 ET | 3500 | 12.595 |
| 09:57 ET | 300 | 12.565 |
| 09:59 ET | 2200 | 12.47 |
| 10:01 ET | 1200 | 12.39 |
| 10:06 ET | 3700 | 12.41 |
| 10:08 ET | 600 | 12.32 |
| 10:10 ET | 200 | 12.32 |
| 10:12 ET | 1500 | 12.35 |
| 10:14 ET | 100 | 12.37 |
| 10:15 ET | 819 | 12.34 |
| 10:17 ET | 6288 | 12.34 |
| 10:19 ET | 732 | 12.315 |
| 10:21 ET | 1065 | 12.315 |
| 10:24 ET | 700 | 12.3 |
| 10:26 ET | 100 | 12.296 |
| 10:28 ET | 3100 | 12.305 |
| 10:30 ET | 2300 | 12.39 |
| 10:32 ET | 1000 | 12.43 |
| 10:33 ET | 6001 | 12.425 |
| 10:35 ET | 500 | 12.43 |
Apr 16, 2024
Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares, from 6:21PM ET on Tuesday Apr 16, 2024 by Dow Jones
6:21PM ET on Tuesday Apr 16, 2024 by Dow Jones
Apr 11, 2024
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering, from 11:38PM ET on Thursday Apr 11, 2024 by Dow Jones
11:38PM ET on Thursday Apr 11, 2024 by Dow JonesPress Release: Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering, from 11:38PM ET on Thursday Apr 11, 2024 by Dow Jones
11:38PM ET on Thursday Apr 11, 2024 by Dow JonesDJ Shares of Nurix Therapeutics Down 6% on Plans for Stock Sale, from 7:27PM ET on Thursday Apr 11, 2024 by Dow Jones
7:27PM ET on Thursday Apr 11, 2024 by Dow JonesDJ Nurix Therapeutics Launches $125M Stock Offering, from 4:19PM ET on Thursday Apr 11, 2024 by Dow Jones
4:19PM ET on Thursday Apr 11, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Nurix Therapeutics Inc | 733.0M | -4.7x | --- |
Y-mAbs Therapeutics Inc | 649.7M | -29.6x | --- |
Regenxbio Inc | 787.6M | -2.7x | --- |
SAGE Therapeutics Inc | 816.2M | -1.6x | --- |
Zymeworks Inc | 572.3M | -4.7x | --- |
CureVac NV | 517.3M | -1.6x | --- |
Company Information
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecules and antibody therapies based on the modulation of cellular protein levels as a treatment approach for cancer, inflammatory conditions and other diseases. It DELigase is an integrated discovery platform, to identify and advance drug candidates targeting E3 ligases. Its drug candidates include NX-2127, NX-5948 and NX-1607. NX-2127 is an orally bioavailable Brutons tyrosine kinase (BTK) degrader that also degrades cereblon neosubstrates IKZF1 (Ikaros) and IKZF3 (Aiolos) for the treatment of relapsed or refractory B-cell malignancies. NX-5948 is an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and potentially autoimmune diseases. NX-1607 is an oral clinical-stage small molecule drug candidate that inhibits Casitas B-lineage lymphoma proto-oncogene-B (CBL-B).
Contact Information
- Headquarters
- 1700 Owens St Ste 205SAN FRANCISCO, CA, United States 94158-0006
- Phone
- 415-660-5320
- Fax
- 415-525-4200
Executives
- Independent Chairman of the Board
- David Lacey
- President, Chief Executive Officer, Director
- Arthur Sands
- Chief Financial Officer
- Hans van Houte
- Chief Scientific Officer
- Gwenn Hansen
- Chief Legal Officer, Chief Compliance Officer, Secretary
- Christine Ring
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $733.0M |
|---|---|
Revenue (TTM) | $80.9M |
Shares Outstanding | 59.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.09 |
EPS | $-2.65 |
Book Value | $4.12 |
P/E Ratio | -4.7x |
Price/Sales (TTM) | 9.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -194.51% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
